Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: Clinical utility and patient considerations

Patient Preference and Adherence

Volumn 9, Issue , 2015, Pages 299-310

  Cruciani, Mario ^a   Malena, Marina ^a  

^a San Bonifacio Hospital   (Italy)

Author keywords

Abacavir lamivudine; Antiretroviral agents; Dolutegravir; HIV 1; Review

Indexed keywords

ABACAVIR; ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR; TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC REACTION; COMPARATIVE EFFECTIVENESS; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MANAGED CARE; PATIENT ATTITUDE; PATIENT SELECTION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84922960278     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S65199     Document Type: Review

References (87)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 27, 2015.
2. European AIDS Clinical Society. Guidelines. Clinical Management and Treatment of HIV Infected Adults in Europe. 7.1. November 2014. Available at: http://www.eacsociety.org/Portals/0/GUIDELINES/English%20PDF%20-%20Version%207.1.pdf. Accessed January 27, 2015.
3. Cruciani M, Mengoli C, Malena M, et al. Virological efficacy of abacavir: systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(12):3169–3180.
4. Rokx C, Fibriani A, van de Vijver DA, et al; for the AIDS Therapy Evaluation in the Netherlands (ATHENA) National Observational Cohort. Increased virological failure in naïve HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch Nationwide ATHENA Cohort. Clin Infect Dis. 2015;60(1):143–153.
5. Ford N, Hill A, Vitoria M, Mills EJ. Comparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohorts. Clin Infect Dis. 2015;60(1):154–156.
6. Ford N, Shubber Z, Hill A, et al. Comparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One. 2013;8:e79981.
7. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–732.
8. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–1122.
9. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–579.
10. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–1735.
11. Sabin CA, Worm SW, Weber R, et al. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet. 2008;371(9622):1417–1426.
12. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17–F24.
13. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201(3):318–330.
14. Aberg JA, Ribaudo H. Cardiac risk: not so simple. J Infect Dis. 2010; 201(3):315–317.
15. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS. 2010;24(3):387–394.
16. Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7(27):iii–x, 1–173.
17. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 Glaxo Smith Kline sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51(1):20–28.
18. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS. 2011;25(16):1993–2004.
19. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61(4):441–447.
20. Lang S, Mary-Krause M, Cotte L, et al. Clinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170(14):1228–1238.
21. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84–91.
22. Ribaudo HJ, Benson CA, Zheng Y, et al; for the ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52(7):929–940.
23. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr. 2009;50(1):54–64.
24. Moyle GJ, Stellbrink HJ, Compston J, et al. 96-week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naïve, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18(7):905–913.
25. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230–2240.
26. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23(12):1547–1556.
27. Pappa K, Hernandez J, Ha B, et al. Abacavir/lamivudine shows robust virologic responses in ART-naïve patients for baseline (BL) viral loads of >100,000 c/mL and <100,000 c/mL by endpoint used in ACTG5202. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract THAB0304.
28. Tan DH, Chan K, Raboud J, et al. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naïve HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr. 2011;58(1):38–46.
29. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
30. Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother. 2010;65(12):2485.
31. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology. 2008;5:114.
32. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646–650.
33. Mesplède T, Quashie PK, Zanichelli V, Wainberg MA. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med. 2014;46(3):123–129.
34. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009;48(7):931–939.
35. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50(4):605–612.
36. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–354.
37. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796.
38. Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–816.
39. Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013;13(7):587–596.
40. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009;52(3):350–356.
41. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46(2):125–133.
42. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus coformulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–2448.
43. Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;63(1):96–100.
44. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429–2438.
45. Shah BM, Schafer J, Priano J, Squires KE. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013;33(10):1107–1116.
46. Gilead Sciences, Inc. Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) [package insert]. Foster City, CA; 2012.
47. Mesplede T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7:401–408.
48. van Lunzen J, Maggiolo F, Arribas J, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–118.
49. Stellbrink H, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naïve adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013;27:1771–1778.
50. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
51. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743.
52. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–935.
53. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222–2231.
54. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir vs raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–708.
55. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207(5):740–748.
56. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–362.
57. Fernandez-Montero JV, Barreiro P, Labarga P, De Mendoza C, Soriano V. Dolutegravir, abacavir and lamivudine as HIV therapy. Expert Opin Pharmacother. 2014;15(7):1051–1057.
58. Raffi F, Pozniak A, Wainberg M. Has the time come to abandon efavirenz for first-line antiretroviral therapy? J Antimicrob Chemother. 2014;69(7):1742–1747.
59. Osterholzer DA, Goldman M. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Clin Infect Dis. 2014;59(2):265–271.
60. Temesgen Z, Talwani R, Rizza SA. Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2014;50(1):7–14.
61. Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353–361.
62. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990–996.
63. Maggi P, Montinaro V, Rusconi S, et al. The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. HIV Clin Trials. 2014;15:87–91.
64. Malet I, Gimferrer Arriaga L, Artese A, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother. 2014;69(8):2118–2122.
65. Hurt CB, Sebastian J, Hicks CB, Eron JJ. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clin Infect Dis. 2014;58(3):423–431.
66. Mesplède T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS. 2012;7(5):401–408.
67. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204–1214.
68. Oliveira M1, Mesplède T, Quashie PK, Moïsi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS. 2014;28(6):813–819.
69. Rodriguez-Rosado R, Jimenez-Nacher I, Soriano V, et al. Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS. 1998;12(9):1112–1113.
70. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17(13):1925–1932.
71. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158–163.
72. Bangsberg D. Less than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–941.
73. Shah B, Walshe L, Saple DG, et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis. 2007;44(9):1235–1244.
74. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8(5):282–292.
75. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationship for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20(2):223–231.
76. Bangsberg DR, Porco TC, Kagay C, et al. Modelling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis. 2004;190(1):162–165.
77. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV infected patients. HIV Clin Trials. 2002;3(5):371–378.
78. Trotta MP, Ammassari A, Cozzi-Lepri A, et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than those receiving protease inhibitor-containing regimens. AIDS. 2003;17(7):1099–1102.
79. Flandre P, Peytavin G, Meifreddy V, et al. Adherence to antiretroviral therapy and outcomes in HIV infected patients enrolled in an induction/maintenance randomized trial. Antivir Ther. 2002;7(2):113–121.
80. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity of HIV-infected patients on antiretroviral therapy. Self-report of the relative importance of multiple attributes of Highly Active Antiretroviral Therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808–816.
81. Boyle B, Jayaweera D, Witt MD, et al. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9(3):164–176.
82. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4:115–125.
83. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients. The Swiss HIV Cohort study. J Acquir Immune Defic Syndr. 2006;41(3):385–392.
84. Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011;25(12):1481–1487.
85. Murray M, Goodqin B, Hagins D, Gallien S, Brennan C, Min S. Measuring patient satisfaction with HIV treatments: comparing dolutegravir with darunavir/r in the FLAMINGO study. Presented at: 20th International AIDS Conference; July 20–25, 2014; Melbourne, Australia. Poster WEPE065.
86. Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006;9(5):20–33.
87. Wu G, Abraham T, Saad N. Dolutegravir for the treatment of adult patients with HIV-1 infection. Expert Rev Anti Infect Ther. 2014;12(5):535–544.